Brimonidine Effectual for Soaring Rates of Glaucoma

Brimonidine Effectual for Soaring Rates of Glaucoma


By 2020 Glaucoma is predicted to affect over 80 million people worldwide as one of the leading causes of vision loss in adults. Approximately 10 percent of the patients diagnosed with Glaucoma will become bilaterally blind from this disease. Treatment to effectively and safely lower intraocular pressure is a must, with a growing rate of patients needing tolerable therapy expected in the next half decade. Brimonidine has, and continues to be an efficacious treatment for lowering intraocular pressure (IOP) in patients by delaying the progressive degeneration of retinal ganglion cells, which leads to elevated IOP. Known as the brand name eye drop Alphagan, which is marketed by Allergan, Brimonidine is now offered in a generic formula from Falcon Pharmaceuticals. As a selective α2-adrenergic receptor agonist, Brimonidine has also proven in a plethora of studies to have protective effects on oxidative stress and glutamate neurotoxicity in the eye. The typical dosage of Brimonidine is one drop in each affected eye, three times a day. This dosing regimen also aids in decreasing fluid production in the eye by increasing draining effectively.

Brimonidine is available as a 0.15% Ophthalmic Solution and can be used alongside the majority of other prescribed eye drops, as long as dosages are spaced at least five minutes apart. Adverse effects from Brimonidine Tartrate are rare, and mild side effects commonly reported include nasal dryness and slight taste perversion. A unique and easy to use Drop-tainer dispenser, marketed by Alcon is available for dosing Brimonidine, in sizes of 5mL, 10mL and 15mL.

LGM Pharma can assist clients as a supplier/distributor of the API’s Brimonidine CAS# 59803-98-4 and Brimonidine Tartrate CAS# 79570-19-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service